Literature DB >> 25795633

The anticipated next season of EGFR inhibitors.

Lecia V Sequist1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25795633      PMCID： PMC4391775          DOI： 10.1634/theoncologist.2015-0086

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  7 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

2.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

3.  Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Authors:  Mauricio Burotto; Elisabet E Manasanch; Julia Wilkerson; Tito Fojo
Journal:  Oncologist       Date:  2015-03-20

Review 4.  Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

Authors:  Chee Khoon Lee; Chris Brown; Richard J Gralla; Vera Hirsh; Sumitra Thongprasert; Chun-Ming Tsai; Eng Huat Tan; James Chung-Man Ho; Da Tong Chu; Adel Zaatar; Jemela Anne Osorio Sanchez; Vu Van Vu; Joseph Siu Kie Au; Akira Inoue; Siow Ming Lee; Val Gebski; James Chih-Hsin Yang
Journal:  J Natl Cancer Inst       Date:  2013-04-17       Impact factor: 13.506

5.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

6.  Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.

Authors:  Benjamin Haaland; Pui San Tan; Gilberto de Castro; Gilberto Lopes
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

7.  Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Authors:  Wenhua Liang; Xuan Wu; Wenfeng Fang; Yuanyuan Zhao; Yunpeng Yang; Zhihuang Hu; Cong Xue; Jing Zhang; Jianwei Zhang; Yuxiang Ma; Ting Zhou; Yue Yan; Xue Hou; Tao Qin; Xiaoxiao Dinglin; Ying Tian; Peiyu Huang; Yan Huang; Hongyun Zhao; Li Zhang
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.